Starpharma Holdings Ltd has released a press release.
DEP HER2-radiodiagnostic shows imaging benefits
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Clinical Trial Update
- Starpharma CEO to retire in 2024
- VIRALEZE Nasal Spray Approved in Malaysia
- HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
- Interim Report and Half-Year Financial Results
Later from Starpharma
- Starpharma partners with UQ to advance DEP radio pipeline
- Pause in Trading
- Trading Halt
- Partnered Program Update
- SPL to receive $6.5M from Mundipharma and VivaGel BV rights
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma